Dexmethylphenidate HCl - CAS 19262-68-1
Catalog number: 19262-68-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C14H20ClNO2
Molecular Weight:
269.77
COA:
Inquire
Targets:
Dopamine Receptor
Description:
Dexmethylphenidate HCl, a synthetic sympathomimetic controlled amine with CNS stimulating properties used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy.
Purity:
>98%
Appearance:
Solid powder
Synonyms:
methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride; Dexmethylphenidate; Dexmethylphenidate Hydrochloride; Focalin; Focalin XR; Hydrochloride, Dexmethylphenidate; XR, Focalin
Solubility:
Methanol
MSDS:
Inquire
InChIKey:
JUMYIBMBTDDLNG-OJERSXHUSA-N
InChI:
1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
Canonical SMILES:
COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl
1.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.
Weisler RH;Childress AC Prim Care Companion CNS Disord. 2011;13(6). pii: PCC.11r01168. doi: 10.4088/PCC.11r01168.
OBJECTIVE: ;To review the efficacy, safety, and abuse liability of approved treatments in adults with attention-deficit/hyperactivity disorder (ADHD), with a focus on once-daily medications.;DATA SOURCES: ;PubMed was searched for relevant studies/reviews in English from 2002 to 2011 on adult ADHD treatments.;STUDY SELECTION: ;Keywords used in the search were ADHD, adults, and treatment. Limits included only clinical trials, meta-analyses, randomized controlled trials, and reviews including adults (aged ≥ 19 years).;DATA EXTRACTION: ;Selection criteria returned 471 publications. Retrieved studies were excluded if they primarily focused on children, treatments not indicated for ADHD, or ADHD and comorbid conditions.;DATA SYNTHESIS: ;An epidemiologic survey revealed that 10.9% of adults identified with ADHD had received treatment during the prior 12 months. Treatments for ADHD in adults include pharmacologic and nonpharmacologic options. US Food and Drug Administration-approved long-acting stimulants and a nonstimulant with proven efficacy and safety profiles have been developed and include osmotic-release oral system methylphenidate hydrochloride (OROS-methylphenidate), extended-release dexmethylphenidate hydrochloride, mixed amphetamine salts extended release (MAS-XR), the nonstimulant atomoxetine hydrochloride, and the prodrug lisdexamfetamine dimesylate.
2.Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review.
Abelman DD Harm Reduct J. 2017 Oct 6;14(1):68. doi: 10.1186/s12954-017-0194-6.
As postsecondary students' use of "study drugs" becomes more popular with increasingly reported negative effects on health and academic performance, failing prohibitionist policies to reduce consumption, and ambiguity in literature towards best practices to address this population, we present a literature review that seeks effective solutions educational institutions can apply to improve outcomes for students who use drugs. Motivations for use, effects of the substances, an analysis of efforts to control use from educational institutions, and suggestions on promoting most effective outcomes based on harm reduction, are described. Theory, quantitative, and qualitative works from systematic reviews, cohort studies, and epidemiological assessments are examined on the "study drugs" methylphenidate, dextroamphetamine, and amphetamine, also known as Adderall, Ritalin, Focalin, and Concerta. There is a focus on postsecondary students ages 18-25 in North America. Results show important risk factors for drug use including low perceived self-efficacy or enjoyment in courses, poor accommodation of special needs, reliance on external validation, having a low GPA, and experiencing a mental health issue.
3.An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B;Sopko MA Jr;Ehret MJ;Paulino RE;Goldberg KR;Angstadt K;Bogart GT Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26.
OBJECTIVE: ;To review recent literature on the different stimulant preparations regarding efficacy and safety in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and describe advantages and disadvantages of the many available dosage formulations.;DATA SOURCES: ;Literature retrieval was performed through PubMed/MEDLINE (2005-December 2008) using the terms methylphenidate, amphetamines, central nervous system stimulants, and attention-deficit/hyperactivity disorder. In addition, reference citations from publications identified were reviewed and drug manufacturers were contacted for any possible additional references.;STUDY SELECTION AND DATA EXTRACTION: ;Double-blind clinical trials found using the search criteria listed above were included for review. Open-label studies and studies prior to 2005 were included if no double-blind trials were published for that formulation within the time period reviewed.;DATA SYNTHESIS: ;The literature reviewed here demonstrates the efficacy and safety of stimulant medications in children and adolescents with ADHD. However, there are 19 different formulations of stimulants, leading to confusion and errors in prescribing and dispensing of these drugs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 115092-85-8 Carmoxirole hydrochloride

Carmoxirole hydrochloride
(CAS: 115092-85-8)

The hydrochloride salt form of Carmoxirole , which is a selective, peripherally acting dopamine D2 receptor agonist and exhibits antihypertensive activities in ...

CAS 854924-64-4 ST 198

ST 198
(CAS: 854924-64-4)

ST 198 is a dopamine D3 receptor antagonist.

CAS 1227675-51-5 SCH 39166 hydrobromide

SCH 39166 hydrobromide
(CAS: 1227675-51-5)

SCH 39166 hydrobromide is a high affinity dopamine D1/D5 receptor antagonist (Ki = 1.2, 2, 980, 5520, 80 and 731 nM for binding to D1, D5, D2, D4, 5-HT and α2a ...

CAS 440-17-5 Trifluoperazine Hydrochloride

Trifluoperazine Hydrochloride
(CAS: 440-17-5)

Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 nM.

CAS 146-56-5 Fluphenazine DiHCl

Fluphenazine DiHCl
(CAS: 146-56-5)

Fluphenazine DiHCl is the dihydrochloride salt preparation of Fluphenazine. It has been used to deliver Fluphenazine to biological systems in studies probing th...

Aripiprazole lauroxil
(CAS: 1259305-29-7)

Aripiprazole lauroxil is a Dopamine D2 receptor agonist, Serotonin 1A receptor agonist and ISerotonin 2A receptor antagonist under the development of Alkermes p...

CAS 59-92-7 Levodopa

Levodopa
(CAS: 59-92-7)

Levodopa (Sinemet) is an amino acid precursor of dopamine with antiparkinsonian properties.

CAS 52-86-8 Haloperidol

Haloperidol
(CAS: 52-86-8)

Haloperidol (Haldol) is an antipsychotic and butyrophenone.

Chemical Structure

CAS 19262-68-1 Dexmethylphenidate HCl

Quick Inquiry

Verification code

Featured Items